Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPN59011 for Moderate to Severe Upper Facial Lines
NCT04736745Phase 1Terminated
- Sponsor
- Ipsen
- Start
- Feb 2021
- Primary completion
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IPN-59011 in glabellar lines and lateral canthal rhytides (4 arms), sponsored by Ipsen. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 9 months, Incidence of Serious Adverse Events at 9 months and 5 more. Started Feb 2021; status: terminated.
02
Drugs
IPN-59011
03
Conditions
glabellar lineslateral canthal rhytides
Beyond the preview
Go deeper on NCT04736745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04736745.